Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

472 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Predictors of cardiovascular events in patients with type 2 diabetic nephropathy and hypertension: a case for albuminuria.
Anavekar NS, Gans DJ, Berl T, Rohde RD, Cooper W, Bhaumik A, Hunsicker LG, Rouleau JL, Lewis JB, Rosendorff C, Porush JG, Drury PL, Esmatjes E, Raz I, Vanhille P, Locatelli F, Goldhaber S, Lewis EJ, Pfeffer MA. Anavekar NS, et al. Among authors: raz i. Kidney Int Suppl. 2004 Nov;(92):S50-5. doi: 10.1111/j.1523-1755.2004.09213.x. Kidney Int Suppl. 2004. PMID: 15485418 Free article. Review.
Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy.
Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL, Drury PL, Esmatjes E, Hricik D, Parikh CR, Raz I, Vanhille P, Wiegmann TB, Wolfe BM, Locatelli F, Goldhaber SZ, Lewis EJ; Irbesartan Diabetic Nephropathy Trial. Collaborative Study Group. Berl T, et al. Among authors: raz i. Ann Intern Med. 2003 Apr 1;138(7):542-9. doi: 10.7326/0003-4819-138-7-200304010-00010. Ann Intern Med. 2003. PMID: 12667024 Clinical Trial.
Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial.
Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL, Drury PL, Esmatjes E, Hricik D, Pohl M, Raz I, Vanhille P, Wiegmann TB, Wolfe BM, Locatelli F, Goldhaber SZ, Lewis EJ; Collaborative Study Group. Berl T, et al. Among authors: raz i. J Am Soc Nephrol. 2005 Jul;16(7):2170-9. doi: 10.1681/ASN.2004090763. Epub 2005 Jun 1. J Am Soc Nephrol. 2005. PMID: 15930097
Effects of sulodexide in patients with type 2 diabetes and persistent albuminuria.
Heerspink HL, Greene T, Lewis JB, Raz I, Rohde RD, Hunsicker LG, Schwartz SL, Aronoff S, Katz MA, Eisner GM, Mersey JH, Wiegmann TB; Collaborative Study Group. Heerspink HL, et al. Among authors: raz i. Nephrol Dial Transplant. 2008 Jun;23(6):1946-54. doi: 10.1093/ndt/gfm893. Epub 2007 Dec 18. Nephrol Dial Transplant. 2008. PMID: 18089623 Clinical Trial.
Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial.
Lewis EJ, Lewis JB, Greene T, Hunsicker LG, Berl T, Pohl MA, de Zeeuw D, Heerspink HL, Rohde RD, Atkins RC, Reutens AT, Packham DK, Raz I; Collaborative Study Group. Lewis EJ, et al. Among authors: raz i. Am J Kidney Dis. 2011 Nov;58(5):729-36. doi: 10.1053/j.ajkd.2011.06.020. Epub 2011 Aug 26. Am J Kidney Dis. 2011. PMID: 21872376 Clinical Trial.
Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy.
Packham DK, Wolfe R, Reutens AT, Berl T, Heerspink HL, Rohde R, Ivory S, Lewis J, Raz I, Wiegmann TB, Chan JC, de Zeeuw D, Lewis EJ, Atkins RC; Collaborative Study Group. Packham DK, et al. Among authors: raz i. J Am Soc Nephrol. 2012 Jan;23(1):123-30. doi: 10.1681/ASN.2011040378. Epub 2011 Oct 27. J Am Soc Nephrol. 2012. PMID: 22034636 Free PMC article. Clinical Trial.
Pyridorin in type 2 diabetic nephropathy.
Lewis EJ, Greene T, Spitalewiz S, Blumenthal S, Berl T, Hunsicker LG, Pohl MA, Rohde RD, Raz I, Yerushalmy Y, Yagil Y, Herskovits T, Atkins RC, Reutens AT, Packham DK, Lewis JB; Collaborative Study Group. Lewis EJ, et al. Among authors: raz i. J Am Soc Nephrol. 2012 Jan;23(1):131-6. doi: 10.1681/ASN.2011030272. Epub 2011 Oct 27. J Am Soc Nephrol. 2012. PMID: 22034637 Free PMC article. Clinical Trial.
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial.
Udell JA, Bhatt DL, Braunwald E, Cavender MA, Mosenzon O, Steg PG, Davidson JA, Nicolau JC, Corbalan R, Hirshberg B, Frederich R, Im K, Umez-Eronini AA, He P, McGuire DK, Leiter LA, Raz I, Scirica BM; SAVOR-TIMI 53 Steering Committee and Investigators. Udell JA, et al. Among authors: raz i. Diabetes Care. 2015 Apr;38(4):696-705. doi: 10.2337/dc14-1850. Epub 2014 Dec 31. Diabetes Care. 2015. PMID: 25552421 Clinical Trial.
Frequency of cancer events with saxagliptin in the SAVOR-TIMI 53 trial.
Leiter LA, Teoh H, Mosenzon O, Cahn A, Hirshberg B, Stahre CA, Hoekstra JB, Alvarsson M, Im K, Scirica BM, Bhatt DL, Raz I; SAVOR-TIMI 53 Steering Committee and Investigators. Leiter LA, et al. Among authors: raz i. Diabetes Obes Metab. 2016 Feb;18(2):186-90. doi: 10.1111/dom.12582. Epub 2015 Nov 27. Diabetes Obes Metab. 2016. PMID: 26443993 Clinical Trial.
472 results